GSK announced on Thursday that its subsidiary ViiV Healthcare has received approval from China’s National Medical Products Administration for ‘Vocabria’, or cabotegravir, injection in combination with Janssen’s ‘Rekambys’ for treating HIV-1 in adults. The approval followed the prior authorisation of cabotegravir injection and tablets in China in July. It said the combination therapy was an alternative to daily oral medication for people with HIV-1 and addressed potential adherence challenges, given that more than one million people were living with HIV in China as of October 2020.
GSK announced on Thursday that its subsidiary ViiV Healthcare has received approval from China’s National Medical Products Administration for ‘Vocabria’, or cabotegravir, injection in combination with Janssen’s ‘Rekambys’ for treating HIV-1 in adults. The approval followed the prior authorisation of cabotegravir injection and tablets in China in July. It said the combination therapy was an alternative to daily oral medication for people with HIV-1 and addressed potential adherence challenges, given that more than one million people were living with HIV in China as of October 2020.